Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations (readOnlyHint, openWorldHint, idempotentHint) already indicate safe, repeatable behavior. The description adds substantial context: data sources (SEC EDGAR/XBRL, FAERS, FDA, ClinicalTrials), specific financial metrics, handling of off-calendar fiscal years, sorting by primary metric, and citation URI format. No contradictions with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is a single paragraph that packs extensive information. It is front-loaded with example queries and includes necessary details. While dense, it is still relatively concise for the complexity, though minor restructuring could improve readability.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the tool's complexity (two entity types, diverse data sources, sorting, citations) and the lack of an output schema, the description is remarkably complete. It covers return format (paired data + citation URIs), sorting behavior, and edge cases (off-calendar fiscal years), leaving no major gaps.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, but the description adds richness beyond the schema: for 'type', it explains data sources and metrics; for 'values', it gives concrete examples (tickers/CIKs, drug names) and constraints. This significantly aids parameter understanding.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool does side-by-side comparison of 2-5 companies or drugs. It provides example queries like 'Compare X and Y' and explicitly distinguishes from sequential lookups, making the purpose unambiguous.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'ALWAYS PREFER over sequential single-pack lookups when comparing entities', giving strong usage guidance. It also details when to use each type (company vs drug) and what data to expect, though it doesn't mention when not to use or alternatives.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.5/5.0
Disambiguation2/5

Several tools have heavily overlapping purposes: ask_pipeworx, ask_pipeworx_beta, and ask_pipeworx_grounded are near-identical, and the five polymarket_* tools (arbitrage, edges, edge_tracker, fill_risk, kalshi_spread) all target prediction-market opportunities. The memory tools (remember/recall/forget) are distinct, as are subscriptions, but the routing and Polymarket clusters create real misselection risk.

Naming Consistency3/5

All names are snake_case, but the pattern is mixed: some are verb_noun (ask_pipeworx, compare_entities, discover_tools, resolve_entity), some are noun_verb or adjective_noun (bet_research, entity_profile, pipeworx_trending, recent_changes), and some are bare nouns/verbs (lookup, query, recall, relatedness). The 'polymarket_*' and 'ask_pipeworx*' families are consistent internally, but the overall set lacks a uniform verb-first convention.

Tool Count2/5

With 34 tools, the server is heavily over-scoped for a server named 'Conceptnet' — the vast majority of tools belong to a separate Pipeworx data-access product, not a semantic-network API. While each tool has a use, the count feels bloated and the server name misrepresents the actual surface.

Completeness4/5

The ConceptNet portion is complete (lookup, query, relatedness cover graph traversal). The Pipeworx portion is also fairly complete: universal router, grounded mode, deep research, entity profiles, comparisons, claim validation, subscription lifecycle, memory, and feedback. Minor gaps exist (e.g., no direct SEC filing fetch without going through ask_pipeworx), but the meta-tools mostly fill them.